US EditionBioVaxys Issues Corporate Update
- On June 3, 2025, BioVaxys Technology Corp. Provided a corporate update from Vancouver, BC, detailing its current operating initiatives and recent financial arrangements.
- The update follows BioVaxys' acquisition in February 2024 of DPX platform assets from IMV Inc. And includes an amendment reducing a $10 million capital raise milestone to about $2 million.
- BioVaxys is restarting clinical trials such as the DPX-surMAGE study in advanced bladder cancer, expanding its pipeline of immunotherapies and vaccines, and non-exclusively out-licensing the DPX platform for human and animal health.
- A clinical trial combining MVP-S with low-dose cyclophosphamide demonstrated a 21% overall response rate and 63% disease control rate in patients with recurrent ovarian cancer.
- The company aims to drive pipeline growth and reduce risks and funding needs via out-licensing, partnerships, and non-dilutive funding, while acknowledging inherent uncertainties in vaccine development and regulatory approval.
Insights by Ground AI
Does this summary seem wrong?
30 Articles
30 Articles
All
Left
2
Center
10
Right
4
Johnson City Press+29 Reposted by 29 other sources
BioVaxys Issues Corporate Update
VANCOUVER, BC, June 3, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in February 2024 from…
Coverage Details
Total News Sources30
Leaning Left2Leaning Right4Center10Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
13%
C 63%
R 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
